Search

Your search keyword '"Osmanovic, Alma"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Osmanovic, Alma" Remove constraint Author: "Osmanovic, Alma"
233 results on '"Osmanovic, Alma"'

Search Results

2. Recommendations for optimal interdisciplinary management and healthcare settings for patients with rare neurological diseases

3. Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany

5. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

6. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

10. Metabolic syndrome is common in adults with 5q‐spinal muscular atrophy and impacts quality of life and fatigue.

12. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study

19. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

20. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

23. Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis

24. Correlation analysis of gamma dose rate from natural radiation in the test field

27. Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy

28. Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

29. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

30. Heterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients

31. Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy

32. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy

33. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

34. Heterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients

35. Glial Fibrillary Acidic Protein in Cerebrospinal Fluid of Nusinersen-Treated Patients with Spinal Muscular Atrophy

36. An unusual presentation of Huntington’s disease

37. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen

38. Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives

39. Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy

40. Additional file 2 of Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy

41. sj-pdf-1-tan-10.1177_1756286421998902 – Supplemental material for Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy

42. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)

43. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

44. Additional file 1 of Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy

45. Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives

46. Common and rare variant association analyses in Amyotrophic Lateral Sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

47. A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany

49. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients

Catalog

Books, media, physical & digital resources